Table 4.
In vitro antifungal susceptibility of Candida species isolated from 180 candidaemia episodes
| Species | MIC (μg/ml) | No. (%) of isolates by new CBPsa | |||||
|---|---|---|---|---|---|---|---|
| (n = 180) | Antifungal agent | Ranges | MIC 50 | MIC 90 | S | SDD/I | R |
| C. albicans | Fluconazole | ⩽0.5–16 | ⩽1 | 1 | 57 (89.1%) | 5 (7.8%) | 2 (3.1%) |
| (n = 64) | Voriconazole | ⩽0.03–4 | ⩽0.06 | 0.125 | 57 (89.1%) | 3 (4.7%) | 4 (6.3%) |
| Itraconazole | 0.062–1 | ⩽0.125 | 0.125 | NA | NA | NA | |
| Amphotericin B | ⩽0.25–1 | ⩽0.5 | 0.5 | 64 (100%) | 0 | 0 | |
| C. parapsilosis | Fluconazole | ⩽0.5–8 | ⩽1 | ⩽4 | 61 (88.4%) | 6 (8.7%) | 2 (2.9%) |
| (n = 69) | Voriconazole | ⩽0.03–1 | ⩽0.06 | 0.125 | 66 (95.7%) | 2 (2.9%) | 1 (1.4%) |
| Itraconazole | ⩽0.062–0.25 | ⩽0.125 | 0.125 | 67 (97.1%) | 0 | 2 (2.9%) | |
| Amphotericin B | ⩽0.25–1 | ⩽0.5 | 0.5 | 69 (100%) | 0 | 0 | |
| C. glabrata | Fluconazole | ⩽1–16 | 4 | 16 | 0 | 25 (100%) | 0 |
| (n = 25) | Voriconazole | 0.06–2 | 0.125 | 0.25 | NA | NA | NA |
| Itraconazole | ⩽0.125–1 | 0.25 | 1 | NA | NA | NA | |
| Amphotericin B | ⩽0.25–2 | ⩽0.5 | 0.5 | 24 (96%) | 0 | 1 (4%) | |
| C. tropicalis | Fluconazole | ⩽1–⩾128 | 2 | 16 | 11 (61.1%) | 1 (5.6%) | 6 (33.3%) |
| (n = 18) | Voriconazole | ⩽0.06–8 | 0.125 | 4 | 12 (66.7%) | 2 (11.1%) | 4 (22.2%) |
| Itraconazole | ⩽0.125–8 | 0.125 | 2 | 9 (50%) | 0 | 9 (50%) | |
| Amphotericin B | ⩽0.25–0.5 | ⩽0.5 | 0.5 | 18 (100%) | 0 | 0 | |
| C. kruseib,c | Fluconazole | 64–128 | 0 | 0 | 2 (100%) | ||
| (n = 2) | Voriconazole | 0.5–>8 | 1 (50%) | 0 | 1 (50%) | ||
| Itraconazole | 1–>4 | NA | NA | NA | |||
| Amphotericin B | 1 | 2 (100%) | 0 | 0 | |||
| C. famatab | Fluconazole | ⩽1–4 | NA | NA | NA | ||
| (n = 2) | Voriconazole | ⩽0.06–0.125 | NA | NA | NA | ||
| Itraconazole | ⩽0.125–0.125 | NA | NA | NA | |||
| Amphotericin B | ⩽0.25–⩽0.5 | NA | NA | NA | |||
a
Except lack of C. famata specific CBPs, CBPs for Candida susceptibility to fluconazole and voriconazole were obtained from CLSI [21], while CBPs for susceptibility of Candida against itraconazole and amphotericin B were from EUCAST [22].
b
MIC 50 and 90 values were not calculated for antifungal drugs against C. krusei and C. famata due to the small number of C. krusei and C. famata cases.
c
Isolates of C. krusei are considered to be intrinsically resistant to fluconazole. S, susceptible; I, intermediate; SDD, susceptible-dose dependent; R, resistant; NA, non-applicable.